Paul Hastings Advised Lenders in Goldman Sachs Alternatives’ Acquisition of Synthon
Paul Hastings LLP advised the lenders in connection with the financing of Goldman Sachs Alternatives’ acquisition of Synthon, a leading platform specialised in developing, manufacturing, and out-licensing complex generic medicines.
The private equity business at Goldman Sachs Alternatives will acquire a majority stake in Synthon from funds advised by BC Partners, which will continue to own a significant stake.
Partners Ross Anderson and Patrick Bright led the Paul Hastings team, which also included partners Karan Chopra, Reena Gogna and Chiraag Patel, and associates Harry Lee, Fabio Pazzini, Haris Ahmed and Hee-Chan Kang.
More details on the transaction can be found here.
With widely recognized elite teams across 18 core practices, Paul Hastings is a premier law firm with a culture of excellence focused on providing intellectual capital and superior execution globally to the world's leading investment banks, asset managers and corporations.